ATRN

Across TCGA pan-cancer cohorts, ATRN mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ATRN data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ATRN mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATRN expression acts as an unfavorable survival marker, although some lineages such as GBM and CCRCC show a favorable association.

LUAD, COAD, and UCEC are the cancer types where ATRN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.222	0.797	<.001	71	view →
COAD	DFS	Median	II,III,IV	0.869	1.000	.018	24	view →
UCEC	DFS	Quartile	III,IV	0.248	1.000	.008	16	view →
LSCC	OS	Median	All	0.931	1.000	.006	13	view →
PDAC	OS	Median	All	0.816	0.910	.006	9	view →
GBM	OS	Tertile	All	0.975	0.654	.004	4	view →
CCRCC	OS	Median	All	1.000	0.909	.019	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ATRN–LUAD (DFS)

Open the LUAD breakdown →